The Primary objective is:
- Disease-free survival measured as a 5-year rate in patients with localized osteosarcoma treated, according to standard practice, with all the drugs currently registered for the treatment of non-metastatic osteosarcoma (methotrexate, cisplatin, adriamycin, ifosfamide, MTP-PE), according to ABCB1 / P-glycoprotein expression.
The Secondary objectives are:
- Evaluate overall survival in a homogeneous population of patients with non-metastatic osteosarcoma.
- Disease-free survival at 2 and 3 years.

